In vitro activity of FCE 22101, imipenem,and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101 |
| |
| Authors: | A L Barry K E Aldridge S D Allen P C Fuchs E H Gerlach R N Jones M A Pfaller |
| |
| Institution: | (1) The Clinical Microbiology Institute, PO Box 947, 97062 Tualatin, Oregon, USA;(2) Louisiana State University, New Orleans, Louisiana, USA;(3) Indiana University Medical Center, Indianapolis, Indiana, USA;(4) St. Vincent Hospital and Medical Center, Portland, Oregon, USA;(5) St. Francis Regional Medical Center, Wichita, Kansas, USA;(6) University of Iowa Medical Center, Iowa City, Iowa, USA |
| |
| Abstract: | Six geographically separate laboratories within the USA tested 6,198 bacterial isolates against FCE 22101 (a penem), imipenem (a carbapenem) and ceftazidime (a third-generation cephalosporin). Ninety-three percent of 2,749Enterobacteriaceae were inhibited by FCE 22101, while 95 % were susceptible to ceftazidime and 99 % were susceptible to imipenem. FCE 22101 had little activity againstPseudomonas spp. but was active against most gram-positive pathogens, including enterococci. FCE 22101 MICs for standard quality control strains were defined as 0.5–2.0µg/ml forEscherichia coli ATCC 25922, 2–8µg/ml forEnterococcus faecalis ATCC 29212 and 0.06–0.25µg/ml forStaphylococcus aureus ATCC 29213. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
